Gilead Sciences, Inc. vs Energy Fuels Inc Ordinary Shares (Canada) — how do they compare? Gilead Sciences, Inc. trades at $155.6 (market cap $190.38B), while Energy Fuels Inc Ordinary Shares (Canada) trades at $8.31 (market cap $2.21B). The key difference: Gilead Sciences, Inc. is far larger — about 86.1× Energy Fuels Inc Ordinary Shares (Canada)'s market cap, and Gilead Sciences, Inc. pays a 2.14% dividend while Energy Fuels Inc Ordinary Shares (Canada) pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 112 Days and Energy Fuels Inc Ordinary Shares (Canada) for 0 Days on average.
| GILD | UUUU | |
|---|---|---|
Market Cap | $190.38B | $2.21B |
Volume | 5,758,183 | 15,605,017 |
Sector | Health | Energy |
52-Week High | $155.80 | $27.72 |
52-Week Low | $117.85 | $8.34 |
Typical Hold Time | 112 Days | 0 Days |
Enterprise Value | $213.45B | $1.95B |
Dividend Yield | 2.14% | — |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.92, down 1.67% on the day, with strong analyst support (67% buy ratings) and a $153.13 consensus price target. Recent quarterly earnings beat expectations despite a Q2 loss, while revenue growth remains steady. Technical indicators show a bullish trend with support at $147-149 and resistance at $152-154. The company continues expanding HIV treatment access through recent PAHO partnerships.
GILD presents a mixed fundamental picture with strong revenue growth but negative net margins. The stock offers upside to analyst targets but faces execution risks in oncology pipeline development and competitive pressures. Recent institutional selling and high debt levels warrant monitoring, though expanding HIV franchise provides stable cash flow foundation.
Energy Fuels (UUUU) trades at $9.27, down 4.04% amid negative sentiment following a securities fraud investigation announcement. The stock shows weak technical positioning near recent lows with neutral indicators. Fundamentally, the company continues to report significant losses with a -77.3% net income margin despite revenue growth projections, while heavy investment in uranium and rare earth expansion creates substantial cash burn.
While analyst consensus remains bullish with a $21.06 price target representing 127% upside, execution risks are elevated. The securities investigation, persistent losses, and massive capital requirements for growth projects create substantial headwinds. Success depends on the company's ability to fund expansion and achieve profitability in the competitive critical minerals sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Energy Fuels Inc. is a US producer of uranium, vanadium, and rare earth elements. It operates the White Mesa Mill in Utah, the only fully licensed and operating conventional uranium processing facility in the country.
Read more on UUUU →